Galantamine: Therapeutic effects beyond cognition

被引:52
作者
Blesa, R [1 ]
机构
[1] Univ Barcelona, Dept Neurol, Hosp Clin Barcelona, E-08036 Barcelona, Spain
关键词
Alzheimer's disease; dementia; galantamine; outcome measures; activities of daily living; disability assessment for dementia; caregiver time; sleep; Pittsburgh Sleep Quality Index;
D O I
10.1159/000051229
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Decline in cognitive function, especially memory, is the core feature of Alzheimer's disease (AD). However, other characteristic aspects of the disease are also important. These include patients' activities of daily living (ADL), including quality of sleep, behavioural disturbances and the impact of the disease on the caregiver. Therefore, increasing attention is being paid to clinically meaningful outcome measures, such as the Disability Assessment for Dementia (DAD) scale, the Neuropsychiatric Inventory (NPI), caregiver time and the Pittsburgh Sleep Quality Index (PSQI). Galantamine is a new treatment for AD that combines modulation of nicotinic receptors with inhibition of acetylcholinesterase. The present review outlines the positive and sustained effects of this agent on patients' behaviour and daily functioning as well as on caregiver time. In studies of up to 5 months' duration, galantamine-treated patients had a significantly better outcome on ADL than placebo-treated patients, and after 12 months of treatment with galantamine, patients' functional ability was preserved. Galantamine also significantly benefits behavioural disturbances in patients with AD. These functional and behavioural benefits are associated with a decrease in the burden on caregivers, as indicated by a reduction, relative to placebo, in the time spent supervising and assisting patients. These clinical benefits are not offset by disruption of patients' sleep, as has been reported with other cholinergic treatments. Copyright (C) 2000 S. Karger AG. Basel.
引用
收藏
页码:28 / 34
页数:7
相关论文
共 45 条
  • [1] Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117
  • [2] American Psychiatric Association American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, P947, DOI [DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596, 10.1176/appi.books.9780890425596.744053, DOI 10.1176/APPI.BOOKS.9780890425596.744053]
  • [3] THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION
    BARTUS, RT
    DEAN, RL
    BEER, B
    LIPPA, AS
    [J]. SCIENCE, 1982, 217 (4558) : 408 - 417
  • [4] Bores GM, 1996, J PHARMACOL EXP THER, V277, P728
  • [5] BORISON RL, 1995, J CLIN PSYCHOPHAR S1, V15, P24
  • [6] BRODATY H, 1998, HLTH EC DEMENTIA, P33
  • [7] The effects of donepezil in Alzheimer's disease -: Results from a multinational trial
    Burns, A
    Rossor, M
    Hecker, J
    Gauthier, S
    Petit, H
    Möller, HJ
    Rogers, SL
    Friedhoff, LT
    [J]. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 1999, 10 (03) : 237 - 244
  • [8] Buysse D J, 1989, Psychiatry Res, V28, P193
  • [9] CAREGIVER TIME USE - AN OUTCOME MEASURE IN CLINICAL-TRIAL RESEARCH ON ALZHEIMERS-DISEASE
    CLIPP, EC
    MOORE, MJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (02) : 228 - 236
  • [10] ALZHEIMERS-DISEASE - A DISORDER OF CORTICAL CHOLINERGIC INNERVATION
    COYLE, JT
    PRICE, DL
    DELONG, MR
    [J]. SCIENCE, 1983, 219 (4589) : 1184 - 1190